- Home
- TNXP vs NXGL Comparison
TNXP vs NXGL Comparison
Compare TNXP & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- NXGL
- Stock Information
- Founded
- TNXP 2007
- NXGL 1997
- Country
- TNXP United States
- NXGL United States
- Employees
- TNXP N/A
- NXGL N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- NXGL Medical/Dental Instruments
- Sector
- TNXP Health Care
- NXGL Health Care
- Exchange
- TNXP Nasdaq
- NXGL Nasdaq
- Market Cap
- TNXP 19.5M
- NXGL 22.7M
- IPO Year
- TNXP N/A
- NXGL 2021
- Fundamental
- Price
- TNXP $0.61
- NXGL $4.73
- Analyst Decision
- TNXP Strong Buy
- NXGL
- Analyst Count
- TNXP 2
- NXGL 0
- Target Price
- TNXP $53.50
- NXGL N/A
- AVG Volume (30 Days)
- TNXP 202.6M
- NXGL 168.1K
- Earning Date
- TNXP 11-12-2024
- NXGL 11-13-2024
- Dividend Yield
- TNXP N/A
- NXGL N/A
- EPS Growth
- TNXP N/A
- NXGL N/A
- EPS
- TNXP N/A
- NXGL N/A
- Revenue
- TNXP $11,291,000.00
- NXGL $6,729,000.00
- Revenue This Year
- TNXP $64.71
- NXGL $120.47
- Revenue Next Year
- TNXP $24.49
- NXGL $38.19
- P/E Ratio
- TNXP N/A
- NXGL N/A
- Revenue Growth
- TNXP 183.05
- NXGL 90.57
- 52 Week Low
- TNXP $0.12
- NXGL $1.84
- 52 Week High
- TNXP $14.08
- NXGL $5.10
- Technical
- Relative Strength Index (RSI)
- TNXP 75.02
- NXGL 66.45
- Support Level
- TNXP $0.32
- NXGL $4.11
- Resistance Level
- TNXP $0.72
- NXGL $5.10
- Average True Range (ATR)
- TNXP 0.15
- NXGL 0.40
- MACD
- TNXP 0.04
- NXGL 0.08
- Stochastic Oscillator
- TNXP 39.61
- NXGL 78.98
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.